Prof. Dr. Tanja Schneider
Institute for Pharmaceutical Microbiology
tschneider@uni-bonn.de View member: Prof. Dr. Tanja Schneider
Antibiotics (Basel, Switzerland)
Methicillin-resistant (MRSA) regulates resistance to β-lactams via preferential production of an alternative penicillin-binding protein (PBP), PBP2a. PBP2a binds many β-lactam antibiotics with less affinity than PBPs which are predominant in methicillin-susceptible (MSSA) strains. A novel, rather frequent in vitro phenotype was recently identified among clinical MRSA bloodstream isolates, termed "NaHCO-responsiveness". This phenotype features β-lactam susceptibility of certain MRSA strains only in the presence of NaHCO. Two distinct PBP2a variants, 246G and 246E, have been linked to the NaHCO-responsive and NaHCO-non-responsive MRSA phenotypes, respectively. To determine the mechanistic impact of PBP2a variants on β-lactam susceptibility, binding profiles of a fluorescent penicillin probe (Bocillin-FL) to each purified PBP2a variant were assessed and compared to whole-cell binding profiles characterized by flow cytometry in the presence vs. absence of NaHCO. These investigations revealed that NaHCO differentially influenced the binding of the fluorescent penicillin, Bocillin-FL, to the PBP2a variants, with binding intensity and rate of binding significantly enhanced in the 246G compared to the 246E variant. Of note, the NaHCO-β-lactam (oxacillin)-responsive JE2 strain, which natively harbors the 246G variant, had enhanced Bocillin-FL whole-cell binding following exposure to NaHCO. This NaHCO-mediated increase in whole-cell Bocillin-FL binding was not observed in the NaHCO-non-responsive parental strain, COL, which contains the 246E PBP2a variant. Surprisingly, genetic swaps of the coding sites between JE2 and COL did not alter the NaHCO-enhanced binding seen in JE2 vs. COL. These data suggest that the non-coding regions of may be involved in NaHCO-responsiveness. This investigation also provides strong evidence that the NaHCO-responsive phenotype in MRSA may involve NaHCO-mediated increases in both initial cell surface β-lactam binding, as well as ultimate PBP2a binding of β-lactams.
PMID: 35453214
Institute for Pharmaceutical Microbiology
tschneider@uni-bonn.de View member: Prof. Dr. Tanja Schneider